Auvi-q
Loading...Auvi-q Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Auvi‑Q® is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis.
Auvi‑Q® is intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.
Anaphylactic reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria or angioedema.
Auvi‑Q® is intended for immediate self-administration as emergency supportive therapy only and is not a substitute for immediate medical care.
History
There is currently no drug history available for this drug.
Other Information
Auvi‑Q® (epinephrine injection, USP) 0.3 mg and 0.15 mg is an auto-injector and a combination product containing drug and device components.
Auvi‑Q® includes audible (electronic voice instructions, beeps) and visible (LED lights) cues for use.
Each Auvi‑Q® 0.3 mg delivers a single dose of 0.3 mg epinephrine from epinephrine injection, USP (0.3 mL) in a sterile solution.
Each Auvi‑Q® 0.15 mg delivers a single dose of 0.15 mg epinephrine from epinephrine injection, USP (0.15 mL) in a sterile solution.
Auvi‑Q® 0.3 mg and Auvi‑Q® 0.15 mg each contain 0.76 mL epinephrine solution. 0.3 mL and 0.15 mL epinephrine solution is dispensed for Auvi‑Q® 0.3 mg and Auvi‑Q® 0.15 mg, respectively, when activated. The remaining solution is not available for future use and should be discarded.
Each 0.3 mL in Auvi‑Q® 0.3 mg contains 0.3 mg epinephrine, 2.3 mg sodium chloride, 0.5 mg sodium bisulfite, hydrochloric acid to adjust pH, and water for injection. The pH range is 2.2–5.0.
Each 0.15 mL in Auvi‑Q® 0.15 mg contains 0.15 mg epinephrine, 1.2 mg sodium chloride, 0.2 mg sodium bisulfite, hydrochloric acid to adjust pH, and water for injection. The pH range is 2.2–5.0.
Epinephrine is a sympathomimetic catecholamine. Chemically, epinephrine is (-)-3,4-Dihydroxy-α-[(methylamino)methyl]benzyl alcohol with the following structure:
Epinephrine solution deteriorates rapidly on exposure to air or light, turning pink from oxidation to adrenochrome and brown from the formation of melanin.
Auvi‑Q® is not made with natural rubber latex.
Auvi‑Q® instructional and safety systems should be thoroughly reviewed with patients and caregivers prior to use [see PATIENT COUNSELING INFORMATION (17.1)].
Sources
Auvi-q Manufacturers
-
Sanofi-aventis U.s. Llc
![Auvi-q (Epinephrine) Injection [Sanofi-aventis U.s. Llc]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Auvi-q | Sanofi-aventis U.s. Llc
Selection of the appropriate dosage strength (Auvi‑Q® 0.3 mg or Auvi‑Q® 0.15 mg) is determined according to patient body weight.
Patients greater than or equal to 30 kg (approximately 66 pounds or more): Auvi‑Q® 0.3 mg Patients 15 to 30 kg (33 pounds to 66 pounds): Auvi‑Q® 0.15 mgInject Auvi‑Q® intramuscularly or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary.
Each Auvi‑Q® contains a single dose of epinephrine for single-use injection. Since the doses of epinephrine delivered from Auvi‑Q® are fixed, consider using other forms of injectable epinephrine if doses lower than 0.15 mg are deemed necessary.
The prescriber should carefully assess each patient to determine the most appropriate dose of epinephrine, recognizing the life-threatening nature of the reactions for which this drug is indicated. With severe persistent anaphylaxis, repeat injections with an additional Auvi‑Q® may be necessary. More than two sequential doses of epinephrine should only be administered under direct medical supervision [see WARNINGS AND PRECAUTIONS (5.1)].
The epinephrine solution in the viewing window of Auvi‑Q® should be inspected visually for particulate matter and discoloration. Epinephrine is light sensitive and should be stored in the outer case provided to protect it from light [see STORAGE AND HANDLING (16.2)].
Login To Your Free Account